Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension

BACKGROUND: The evidence regarding triple oral combination therapy for patients with pulmonary arterial hypertension (PAH) is scarce. This study was performed to investigate the effectiveness and safety of triple oral combination therapy with macitentan, riociguat, and selexipag. METHODS: Among cons...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Adv Respir Dis
Autors principals: Momoi, Mizuki, Hiraide, Takahiro, Shinya, Yoshiki, Momota, Hiromi, Fukui, Shogo, Kawakami, Michiyuki, Itabashi, Yuji, Fukuda, Keiichi, Kataoka, Masaharu
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7919213/
https://ncbi.nlm.nih.gov/pubmed/33627044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466621995048
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars